WGS Stock Analysis: GeneDx Holdings | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.636m USD | 12M Return: -37.7% | US81663L2007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.1M
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GeneDx Holdings Corp. (NASDAQ: WGS) is a U.S.-based genomics company founded in 2000 and headquartered in Stamford, Connecticut, that delivers genetic testing services with a primary focus on pediatric and rare disease diagnostics. Its core offerings include whole exome and genome sequencing, which analyze either the protein-coding regions or the entirety of a patients DNA to help clinicians identify the genetic causes of complex or rare conditions. The company also provides supporting data and information services tied to its testing platform.
In addition to its diagnostic services, GeneDx is developing an AI-based platform designed to streamline next-generation sequencing analysis, interpretation, and clinical reporting across rare disease, hereditary risk, and cancer testing applications. The company trades on NASDAQ as a mid-cap health care equity and listed publicly in late 2020. As a genomics-focused firm operating within the broader health care sector, GeneDx benefits from growing demand for precision medicine and advanced molecular diagnostics, areas where AI-driven interpretation tools are increasingly viewed as a competitive differentiator.
- Whole exome sequencing revenue accelerates on rising pediatric rare disease demand
- Reimbursement pressure from commercial payers limits gross margin expansion
- Competition from Natera and Invitae pressures genetic testing market share
- Cash burn reduction drives path to profitability milestone
| Net Income: -106.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.16 > 0.02 and ΔFCF/TA -15.92 > 1.0 |
| NWC/Revenue: 37.79% < 20% (prev 36.83%; Δ 0.96% < -1%) |
| CFO/TA -0.10 > 3% & CFO -48.7m > Net Income -106.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.7m) vs 12m ago -0.15% < -2% |
| Gross Margin: 68.20% > 18% (prev 67.18%; Δ 1.01% > 0.5%) |
| Asset Turnover: 96.14% > 50% (prev 78.11%; Δ 18.03% > 0%) |
| Interest Coverage Ratio: -34.62 > 6 (EBIT TTM -103.3m / Interest Expense TTM 2.98m) |
| A: 0.36 (Total Current Assets 246.4m - Total Current Liabilities 74.6m) / Total Assets 481.5m |
| B: -3.02 (Retained Earnings -1.45b / Total Assets 481.5m) |
| C: -0.22 (EBIT TTM -103.3m / Avg Total Assets 472.7m) |
| D: 1.03 (Book Value of Equity 244.2m / Total Liabilities 237.3m) |
| Altman-Z'' = -7.90 = D |
| DSRI: 1.39 (Receivables 83.6m/48.0m, Revenue 454.4m/362.3m) |
| GMI: 0.99 (GM 67.18% / 68.20%) |
| AQI: 0.73 (AQ_t 0.31 / AQ_t-1 0.42) |
| SGI: 1.25 (Revenue 454.4m / 362.3m) |
| TATA: -0.12 (NI -106.4m - CFO -48.7m) / TA 481.5m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of October 05, 2026, the stock is trading at USD 73.09 with a total of 606,659 shares traded. Over the past week, the price has changed by -17.32%, over one month by -15.72%, over three months by +8.27% and over the past year by -37.73%.
Current recommended Stop Loss: 66.00 (which is 9.7% or 1.2 ATR below the current price).
GeneDx Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy WGS.
- StrongBuy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 90.4 | 23.7% |
P/E Forward = 63.2911
P/S = 5.8014
P/B = 10.4034
Revenue TTM = 454.4m USD
EBIT TTM = -103.3m USD
EBITDA TTM = -76.4m USD
Long Term Debt = 96.8m USD (from longTermDebt, last quarter)
Short Term Debt = 5.71m USD (from shortTermDebt, last quarter)
Debt = 238.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 70.6m
Net Debt = 105.4m USD (calculated: Debt 238.0m - CCE 132.5m)
Enterprise Value = 2.74b USD (2.64b + Debt 238.0m - CCE 132.5m)
Interest Coverage Ratio = -34.62 (Ebit TTM -103.3m / Interest Expense TTM 2.98m)
EV/FCF = -36.17x (Enterprise Value 2.74b / FCF TTM -75.8m)
FCF Yield = -2.76% (FCF TTM -75.8m / Enterprise Value 2.74b)
FCF Margin = -16.68% (FCF TTM -75.8m / Revenue TTM 454.4m)
Net Margin = -23.40% (Net Income TTM -106.4m / Revenue TTM 454.4m)
Gross Margin = 68.20% ((Revenue TTM 454.4m - Cost of Revenue TTM 144.5m) / Revenue TTM)
Gross Margin QoQ = 68.37% (prev 66.71%)
Tobins Q-Ratio = 5.69 (Enterprise Value 2.74b / Total Assets 481.5m)
Interest Expense / Debt = 1.25% (Interest Expense 2.98m / Debt 238.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -81.6m (EBIT -103.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.30 (Total Current Assets 246.4m / Total Current Liabilities 74.6m)
Debt / Equity = 0.97 (Debt 238.0m / totalStockholderEquity, last quarter 244.2m)
Debt / EBITDA = -1.38 (negative EBITDA) (Net Debt 105.4m / EBITDA -76.4m)
Debt / FCF = -1.39 (negative FCF - burning cash) (Net Debt 105.4m / FCF TTM -75.8m)
Total Stockholder Equity = 274.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.50% (Net Income -106.4m / Total Assets 481.5m)
RoE = -38.72% (Net Income TTM -106.4m / Total Stockholder Equity 274.7m)
RoCE = -27.81% (EBIT -103.3m / Capital Employed (Equity 274.7m + L.T.Debt 96.8m))
RoIC = -20.94% (negative operating profit) (NOPAT -81.6m / Invested Capital 389.8m)
WACC = 8.09% (E(2.64b)/V(2.87b) * Re(8.73%) + D(238.0m)/V(2.87b) * Rd(1.25%) * (1-Tc(0.21)))
Discount Rate = 8.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.94 | Cagr: 6.00%
[DCF] Fair Price = unknown (Cash Flow -75.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.86 | # QB: 1
Revenue Correlation: 98.98 | Revenue CAGR: 39.50% | SUE: 0.38 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.07 | Chg30d=-36.96% | Revisions=-55% | Analysts=8
EPS current Year (2026-12-31): EPS=0.13 | Chg30d=+15.91% | Revisions=+12% | GrowthEPS=-90.9% | GrowthRev=+12.6%
EPS next Year (2027-12-31): EPS=1.17 | Chg30d=-5.08% | Revisions=+18% | GrowthEPS=+816.7% | GrowthRev=+24.3%
[Analyst] Revisions Ratio: -12% (up=9, down=12)